Groupe d'Etude en Oncologie du Quebec

Titre	Pelvic Nodes Ultra-Hypo Fractionated Versus Conventionally Fractionated IMRT With HDR Brachytherapy Boost in Prostate Cancer: A Collaborative Multi-institutional Non-inferiority Phase 3 Trial.
Protocole ID	PCS-XI
ClinicalTrials.gov ID	NCT05820633
Type(s) de cancer	Prostate
Phase	Phase III
Type étude	Clinique
Institution	CISSS DE LAVAL HOPITAL DE LA CITE-DE-LA-SANTE 1755 boul. René-Laennec, Laval, QC, H7M 3L9
Ville	Laval
Investigateur(trice) principal(e)	Dr Danny Duplan
Coordonnateur(trice)	Imane Benmouhoub 450-668-1010 poste 23671
Statut	Actif en recrutement
Date d'activation	27-02-2024
Critètes d'éligibilité	Histopathologically confirmed adenocarcinoma of the prostate. All clinical stages with lymph node involvement risk needing pelvis RT. Stage Mx or M0. Unfavorable Intermediate, high or very high-risk disease according to NCCN guidelines. Having the ability to give free and informed consent.
Critètes d'exclusion	Clinical stage M1. IPSS Score > 20 with alpha-blocking medication. Prior pelvic radiotherapy, History of active collagenosis (Lupus, Scleroderma, Dermatomyositis). Past history of Inflammatory Bowell Disease. Bilateral hip prosthesis.

Groupe d'étude en oncologie du Québec